Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human Study

Matthew S. Davids(Dana-Farber Cancer Institute), John F. Seymour(The Royal Melbourne Hospital), Andrew W. Roberts(The Royal Melbourne Hospital), Thomas J. Kipps(University of California San Diego), Ahmed Hamed Salem(Ain Shams University), John C. Pesko(AbbVie (United States)), Su Y. Kim(AbbVie (United States)), Michelle Boyer(Amgen (United States)), Jennifer A. Arzt(Universitätsklinikum des Saarlandes), William G. Wierda(University of Maryland, Baltimore), Abhijeet Kumar(Arizona Oncology), Margaret Mantas(AbbVie (United States)), Vaishalee P. Kenkre(University of Wisconsin–Madison)
Clinical Cancer Research
June 3, 2021
10.1158/1078-0432.ccr-20-4842
Cited by 69

Related Papers

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
|Blood|2008|3.2k
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k